ClinicalTrials.gg
TerminatedNCT04644029Impower-022Updated Feb 4, 2026Results posted

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

A Phase 3 interventional study of Islatravir and Placebo to FTC/TDF in HIV-I, Human Immunodeficiency Virus Type 1 and Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Terminated at 24 sites in 3 countries. Open to female participants aged 16 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Why this study was terminated
Voluntarily terminated due to benefit/risk assessment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
16 Years to 45 Years
Sex
Female
01

Study summary

This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection. The study will compare oral ISL taken once a month with standard-of-care medication for prevention of HIV-1 infection, emtricitabine/tenofovir disoproxil (FTC/TDF), taken once per day. The primary hypothesis is that oral ISL is more effective than FTC/TDF at reducing the incidence rate per year of confirmed HIV-1 infections.

Read the detailed description

Based on laboratory findings of decreased lymphocyte and CD4+ T-cell counts across the islatravir program, dosing of blinded study intervention was halted on 13-Dec-2021 and screening and randomization of new participants was ended. Blinded assessments conducted prior to this date are designated as Study Part 1. During Study Part 2, participants from Part 1 have the option to receive daily open-label FTC/TDF while continuing in the study for safety monitoring. Study Part 3 was added to unblind each participant's Part 1 study intervention assignment, continue participants on FTC/TDF, and monitor safety.

02

Conditions studied

  • HIV-I
  • Human Immunodeficiency Virus Type 1
  • Prophylaxis

Browse trials for

Keywords

  • Preexposure prophylaxis (PrEP)
  • Prevention
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 730 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
16 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed -uninfected based on negative HIV-1/HIV-2 test results before randomization.
  • Sexually active (vaginal and/or anal sex) with a male sexual partner in the 30 days prior to screening.
  • High risk for HIV-1 infection.
  • Not pregnant or breastfeeding, and one of the following conditions applies: Not a woman of (WOCBP) or is a WOCBP and is using an acceptable method during the intervention period and for at least 42 days after the last dose.
  • A WOCBP must have a negative pregnancy test within 24 hours prior to the first dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • or other to any of the components of the study interventions as determined by the investigator.
  • Findings of chronic virus (HBV) infection or past HBV.
  • Current or chronic history of liver disease.
  • History of within 5 years of screening except for adequately-treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
  • Past or current use of cabotegravir, lenacapavir, or any other long-acting prevention product.
  • Currently participating in or has participated in an interventional clinical study with an compound or device, within 30 days prior to Day 1.
  • Expecting to conceive or donate eggs at any time during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
730 participants (actual)

Study arms

  • Experimental
    ISL QM

    ISL (islatravir) once monthly AND placebo to FTC/TDF (emtricitabine/tenofovir disoproxil) once daily. Following study-wide cessation of ISL administration, participants had the option to receive open-label FTC/TDF administered once daily.

    Drug: Islatravir · Drug: Placebo to FTC/TDF

  • Active comparator
    FTC/TDF QD

    FTC/TDF (TRUVADA™ or generic product emtricitabine/tenofovir disoproxil) administered once daily. Placebo to ISL (islatravir) administered once monthly. Following study-wide cessation of ISL administration, participants had the option to continue on open-label FTC/TDF. Placebo was no longer administered once open label treatment began.

    Drug: FTC/TDF · Drug: Placebo to ISL

Interventions

  • Oral 60 mg tablet administered once monthly during Part 1.

    Also known as: MK-8591

  • DrugPlacebo to FTC/TDF

    0 mg tablet administered once daily during Part 1.

  • DrugFTC/TDF

    Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.

    Also known as: TRUVADA™, Emtricitabine/Tenofovir disoproxil, Emtricitabine/Tenofovir disoproxil fumarate

  • DrugPlacebo to ISL

    0 mg tablet administered orally once monthly in Part 1.

06

What researchers measure

Primary outcomes

  1. Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-Blind

    Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned primary statistical analysis was removed via amendment when open-label treatment was initiated.

    Time frame: Up to approximately 325 days

  2. Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-Blind

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

    Time frame: Up to approximately 325 days

  3. Number of Participants Who Discontinued Blinded Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued blinded study treatment due to an AE will be reported for each treatment arm.

    Time frame: Up to 283 days

Secondary outcomes

  1. Incidence Rate Per Year During Blinded Treatment of Confirmed HIV-1 Infection Among ISL-Treated Participants

    Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned secondary statistical analysis was removed via amendment when open-label treatment was initiated.

    Time frame: Up to approximately 237 days

07

Results

Posted Aug 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneISL QMFTC/TDF QD
Started364366
Treated per protocol arm design362365
Received open-label ftc/tdf343345
Completed00
Not completed364366
Withdrew: Death10
Withdrew: Physician decision12
Withdrew: Withdrawal by subject2119
Withdrew: Lost to follow-up3134
Withdrew: Study terminated by sponsor308309
Withdrew: Randomized in error21
Withdrew: Other01

Outcome measures

PrimaryIncidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-Blind

Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned primary statistical analysis was removed via amendment when open-label treatment was initiated.

Time frame:
Up to approximately 325 days
Reported as:
Number · Percentage of Participants/Person-Year
Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-Blind
Percentage of Participants/Person-YearISL QMFTC/TDF QD
Incidence Rate Per Year of Confirmed HIV-1 Infection Among Participants During Blinded Treatment +42 Days Post-Blind0.0000.000
PrimaryNumber of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-Blind

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

Time frame:
Up to approximately 325 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-Blind
ParticipantsISL QMFTC/TDF QD
Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment + 42 Days Post-Blind198255
PrimaryNumber of Participants Who Discontinued Blinded Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued blinded study treatment due to an AE will be reported for each treatment arm.

Time frame:
Up to 283 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Blinded Study Treatment Due to an AE
ParticipantsISL QMFTC/TDF QD
Number of Participants Who Discontinued Blinded Study Treatment Due to an AE24
SecondaryIncidence Rate Per Year During Blinded Treatment of Confirmed HIV-1 Infection Among ISL-Treated Participants

Incidence rate per year of confirmed HIV-1 infections is the number of participants with confirmed HIV-1 infections during the assessment period divided by the number of person-years in the arm. Data are based on participants with confirmed HIV-1 infection. The originally planned secondary statistical analysis was removed via amendment when open-label treatment was initiated.

Time frame:
Up to approximately 237 days
Reported as:
Number · Percentage of Participants/Person-Year
Incidence Rate Per Year During Blinded Treatment of Confirmed HIV-1 Infection Among ISL-Treated Participants
Percentage of Participants/Person-YearISL QM
Incidence Rate Per Year During Blinded Treatment of Confirmed HIV-1 Infection Among ISL-Treated Participants0.000

Adverse events

Collected over Blinded arms and mistaken treatment arm: Up to approximately 325 days Open-label arms: Up to approximately 639 days (starting 42 days after last blinded treatment; includes the time leading up to first open-label treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ISL QM1/364 (0.3%)4/362 (1.1%)145/362 (40.1%)
ISL QM > Open-Label FTC/TDF0/343 (0%)13/343 (3.8%)292/343 (85.1%)
FTC/TDF QD0/366 (0%)2/365 (0.5%)210/365 (57.5%)
FTC/TDF > Open-Label FTC/TDF Second Course0/345 (0%)23/345 (6.7%)284/345 (82.3%)
FTC/TDF-Treated Without Randomization0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventISL QMISL QM > Open-Label FTC/TDFFTC/TDF QDFTC/TDF > Open-Label FTC/TDF Second CourseFTC/TDF-Treated Without Randomization
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/3622/3431/3654/3450/1
Prolonged labourPregnancy, puerperium and perinatal conditions0/3620/3430/3652/3450/1
GastritisGastrointestinal disorders0/3621/3430/3650/3450/1
Aspartate aminotransferase increasedInvestigations0/3621/3430/3650/3450/1
Gamma-glutamyltransferase increasedInvestigations0/3621/3430/3650/3450/1
Abnormal loss of weightMetabolism and nutrition disorders0/3621/3430/3650/3450/1
Type 1 diabetes mellitusMetabolism and nutrition disorders0/3621/3430/3650/3450/1
Loss of consciousnessNervous system disorders0/3621/3430/3650/3450/1
SyncopeNervous system disorders0/3621/3430/3650/3450/1
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/3621/3430/3650/3450/1
Most frequent other events
Showing 10 of 22
Most frequent other events
EventISL QMISL QM > Open-Label FTC/TDFFTC/TDF QDFTC/TDF > Open-Label FTC/TDF Second CourseFTC/TDF-Treated Without Randomization
Bacterial vaginosisInfections and infestations28/362158/34357/365143/3450/1
Vulvovaginal candidiasisInfections and infestations13/362114/34329/365109/3450/1
Upper respiratory tract infectionInfections and infestations21/36270/34312/36555/3450/1
HeadacheNervous system disorders43/36261/34353/36556/3450/1
Chlamydial infectionInfections and infestations4/36258/34317/36555/3450/1
Influenza like illnessGeneral disorders4/36245/3433/36541/3450/1
Heavy menstrual bleedingReproductive system and breast disorders13/36233/34311/36539/3450/1
NauseaGastrointestinal disorders19/36213/34341/36513/3450/1
Urinary tract infectionInfections and infestations0/36231/3435/36534/3450/1
Vaginal dischargeReproductive system and breast disorders7/36230/34311/36530/3450/1

Baseline characteristics

The baseline characteristics population includes all randomized participants who received study drug.

Age, Continuous
Age, Continuous(Years)ISL QMFTC/TDF QDTotal
Mean26.0 ± 6.126.1 ± 6.326.1 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)ISL QMFTC/TDF QDTotal
Female362365727
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ISL QMFTC/TDF QDTotal
Hispanic or Latino111324
Not Hispanic or Latino329330659
Unknown or Not Reported222244
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ISL QMFTC/TDF QDTotal
American Indian or Alaska Native112
Asian5611
Native Hawaiian or Other Pacific Islander000
Black or African American334338672
White191534
More than one race347
Unknown or Not Reported011
08

Study locations

24 sites
  • University of Alabama at Birmingham-UAB Sexual Health Research Clinic (SHRC) ( Site 0064)
    Birmingham, Alabama 35205, United States
  • MedStar Health Research Institute (MedStar Physician Based R-MedStar Washington Hospital Center ( Si
    Washington D.C., District of Columbia 20010, United States
  • University of Miami Miller School of Medicine-Infectious Disease ( Site 0076)
    Miami, Florida 33136, United States
  • Orlando Immunology Center ( Site 0068)
    Orlando, Florida 32803, United States
  • Ponce De Leon Center Grady Health ( Site 0066)
    Atlanta, Georgia 30308, United States
  • The University of Mississippi Medical Center ( Site 0065)
    Jackson, Mississippi 39216, United States
  • KC CARE Health Center-Clinical Trials ( Site 0059)
    Kansas City, Missouri 64111, United States
  • Rutgers New Jersey Medical School-Clinical Research Center ( Site 0071)
    Newark, New Jersey 07103, United States
  • Bronx Prevention Center ICAP ( Site 0062)
    The Bronx, New York 10451, United States
  • The University of North Carolina at Chapel Hill-Medicine ( Site 0056)
    Chapel Hill, North Carolina 27599, United States
  • Prisma Health Richland Hospital-Clinical Research Unit ( Site 0069)
    Columbia, South Carolina 29203, United States
  • Prism Health North Texas, Oak Cliff Health Center ( Site 0070)
    Dallas, Texas 75208, United States
  • West Virginia University-Department of Medicine ( Site 0061)
    Morgantown, West Virginia 26506, United States
  • Perinatal HIV Research Unit (PHRU)-HIV Prevention CRS ( Site 0023)
    Johannesburg, Gauteng 1864, South Africa
  • Wits Reproductive Health and HIV Institute (WRHI)-Wits RHI Ward 21 Clinical Research site ( Site 002
    Johannesburg, Gauteng 2000, South Africa
  • Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0020)
    Johannesburg, Gauteng 2092, South Africa
  • Setshaba Research Centre ( Site 0016)
    Pretoria, Gauteng 0152, South Africa
  • SA Medical Research Council - Chatsworth Clinical Research Site ( Site 0030)
    Chatsworth, KwaZulu-Natal 4092, South Africa
  • Maternal Adolescent and Child Health Research (MatCH) ( Site 0025)
    Durban, KwaZulu-Natal 4001, South Africa
  • Qhakaza Mbokodo Research Clinic ( Site 0017)
    Ladysmith, KwaZulu-Natal 3370, South Africa
  • Madibeng Centre for Research ( Site 0019)
    Brits, North West 0250, South Africa
  • Aurum Institute Klerksdorp CRS ( Site 0029)
    Klerksdorp, North West 2571, South Africa
  • Aurum Institute - Rustenburg ( Site 0022)
    Rustenburg, North West 0299, South Africa
  • MU-JHU Care Limited-Clinic ( Site 0041)
    Kampala, 10216, Uganda
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Jul 2023, 28 months.

Results were first posted in Aug 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Nov 25, 2020
StartActual
Feb 24, 2021
Primary completionActual
Jul 18, 2023
CompletionActual
Jun 11, 2024
Results first posted
Aug 9, 2024
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04644029
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Feb 24, 2021
Primary completion
Jul 18, 2023
Completion
Jun 11, 2024
Results posted
Aug 9, 2024
Last update
Feb 4, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Islatravir

Start the discussion